Stryker Corporation (NYSE:SYK) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts remain moderately bullish on Stryker: Twenty-four brokerages give the stock a consensus “Moderate Buy” rating, with 17 buys, six holds, and one strong buy. The average 12-month price target is $386.28.
• Stryker recently exceeded quarterly expectations: The medical technology company reported $3.69 in adjusted EPS versus the $3.49 consensus estimate, while revenue rose 9.4% year over year to $6.59 billion.
• The stock traded down 3.5% to $327.97, while Stryker announced a quarterly dividend of $0.88 per share, equivalent to a 1.1% yield. Insiders sold approximately $216.2 million of stock during the last quarter.

Shares of Stryker Corporation (NYSE:SYK - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-four research firms that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $386.28.

Several brokerages have issued reports on SYK. Raymond James Financial set a $370.00 target price on Stryker in a report on Friday, July 31st. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Piper Sandler cut their price objective on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. Truist Financial lifted their target price on shares of Stryker from $330.00 to $340.00 and gave the stock a "hold" rating in a research note on Friday, July 31st. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $361.00 price target on shares of Stryker in a research note on Friday, May 1st.

Stryker Trading Down 3.5%

SYK opened at $327.97 on Friday. The firm has a market capitalization of $125.80 billion, a price-to-earnings ratio of 33.99, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76. The company's 50 day simple moving average is $326.64 and its two-hundred day simple moving average is $332.66. Stryker has a 1-year low of $281.00 and a 1-year high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. During the same quarter last year, the firm earned $3.13 earnings per share. The business's revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts expect that Stryker will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker's dividend payout ratio (DPR) is 36.48%.

Insider Activity

In related news, insider Debra King sold 826 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 310,000 shares of the business's stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 665,370 shares of company stock valued at $216,238,501 in the last quarter. Insiders own 4.60% of the company's stock.

Institutional Trading of Stryker

Several institutional investors have recently added to or reduced their stakes in SYK. Sankala Group LLC purchased a new position in shares of Stryker during the fourth quarter worth $26,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker in the 4th quarter valued at $26,000. United Financial Planning Group LLC acquired a new position in Stryker during the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker during the 4th quarter worth about $27,000. Finally, Gables Capital Management Inc. purchased a new position in Stryker during the 2nd quarter valued at about $25,000. Institutional investors and hedge funds own 77.09% of the company's stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source